Health Economics›Cholangiocarcinoma›Metastatic disease, subsequent lines of therapy

Metastatic disease, subsequent lines of therapy

Cholangiocarcinoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
mFOLFOX6 Variant #02	—	R 2 617	14d	~8.4 mo	~12.7 mo	~2	~R 5 233 PFS proxy · indirect	15
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 2 054	14d	—	~11.8 mo	~12	~R 24 643 PFS proxy · indirect	3

2 of 2 regimens shown